Baizencell Announces New CAR Signaling Domain Animal Study Results at US SITC
[Asia Economy Reporter Lee Gwan-joo] VigenCell announced on the 6th that it will present the results of animal efficacy studies for the development of CAR-T including the CD30 co-stimulatory domain at the Society for Immunotherapy of Cancer (SITC) to be held next month in Boston, USA.
SITC is the largest global conference in the field of immuno-oncology and is one of the world's top three cancer conferences. This year, SITC will be held in Boston, Massachusetts, USA, from the 8th to the 12th of next month (local time).
The research topic presented by VigenCell is about the results of animal efficacy studies of CAR-T including the CD30 co-stimulatory domain for the development of the 'VR-CAR' pipeline, and a poster presentation will be conducted along with the abstract submission.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- [Breaking] Central Labor Relations Commission: "Second Post-Mediation Fails for Samsung Electronics"
- "Looks Even More Like Him in Person": Crowds Gather to See 'Trump Lookalike' Albino Buffalo
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Tae-gyu Kim, CEO of VigenCell, said, "We are pleased to present the advanced research results of CAR-T at this SITC," and added, "We will strive to develop preclinical research further so that it can be applied to the treatment of liver cancer and other solid tumors."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
